AJP - Heart Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 287: H494-H500, 2004; doi:10.1152/ajpheart.00064.2004
0363-6135/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jevremovic, D.
Right arrow Articles by Vile, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jevremovic, D.
Right arrow Articles by Vile, R. G.

CALL FOR PAPERS
Cellular Plasticity in the Cardiovascular System

Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors

Dragan Jevremovic,1,2 Rajiv Gulati,1,3 Ivo Hennig,1 Rosa Maria Diaz,1 Caroline Cole,1,4 Laurel Kleppe,1,3 Francois Loic Cosset,5 Robert D. Simari,1,3 and Richard G. Vile1,4

1Molecular Medicine Program, 2Division of Pathology, 3Division of Cardiovascular Diseases, and 4Division of Immunology, Mayo Clinic and Foundation, Rochester, Minnesota 55905; and 5Vectorologie Rétrovirale et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale U412, Lyon Cedex 07, France

Submitted 30 March 2004 ; accepted in final form 30 March 2004

Cell-based delivery of therapeutic viruses has potential advantages over systemic viral administration, including attenuated neutralization and improved viral targeting. One of the exciting new areas of investigation is the potential ability of endothelial-lineage cells to deliver genes to the areas of neovascularization. In the present study, we compared two types of endothelial-lineage cells [outgrowth endothelial cells (OECs) and culture-modified mononuclear cells (CMMCs), also known as "endothelial progenitor cells"] for their ability to be infected with adenovirus and to home to the areas of neovascularization. Both cell types were isolated from peripheral blood of healthy human donors and expanded in culture. We demonstrate that OECs are more infectable and home better to tumors expressing VEGF on systemic administration. Furthermore, we used an adenoviral/retroviral chimeric system to convert OECs to retrovirus-producing cells. When injected systemically into tumor-bearing mice, OECs retain their ability to produce retrovirus and infect surrounding tumor cells. Our data demonstrate that OECs could be efficient carriers for viral delivery to areas of tumor neovascularization.

stem cells; gene therapy; viral vectors; cell carriers


Address for reprint requests and other correspondence: R. G. Vile, Mayo Clinic, 18 Gugg, 200 First St. SW, Rochester, MN 55905 (E-mail: vile.richard{at}mayo.edu).




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
S. Komarova, Y. Kawakami, M. A. Stoff-Khalili, D. T. Curiel, and L. Pereboeva
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses.
Mol. Cancer Ther., March 1, 2006; 5(3): 755 - 766.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.